Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Chugai

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Chugai's Japan sales performance.

Myovant preps US filing for relugolix in prostate cancer

Myovant preps US filing for relugolix in prostate cancer of 2020 and in Europe and Japan a little later, says the biotech.

FDA advisors say no to empagliflozin in type 1 diabetes

FDA advisors say no to empagliflozin in type 1 diabetes Europe as well as Japan.

Pharmaceutical innovation in the APAC region

Pharmaceutical innovation in the APAC region We examined these factors for Mainland China, Japan and South Korea, concluding, very broadly:. ... Cancer will remain a growth market, although Japan is currently experiencing price containment pressures that other countries will also ultimately face.

Sandoz expands into Japan with €400m Aspen deal

Sandoz expands into Japan with €400m Aspen deal The acquisition will include shares in Aspen Japan K.K. and all associated assets held by AGI. ... Japan’s generic medicines market is the third largest globally, a fact which will aid Sandoz’ continuing growth – in Novartis’ recent third

Daiichi files lawsuit with Seattle over ADCs, including AZ-partnered DS-8201

Daiichi files lawsuit with Seattle over ADCs, including AZ-partnered DS-8201 Dispute covers multiple drugs in Daiichi's antibody-drug conjugates pipeline. A partnership between Seattle Genetics and Japan’s Daiichi Sankyo on antibody-drug conjugates, which ended in 2015, has sparked

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...
Figure 1 Clarivate
The changing nature of approvals – what does the future hold?
The 2019 CMR International Pharmaceutical R&D Factbook...
Spotlight interview: 15 minutes on healthcare communications in gene therapy
Gavin Jones, Director of Rare Disease, OPEN Health takes 15 minutes to answer some key questions on healthcare communications in gene therapy...

Infographics